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Abstract 
Purpose: To quantify the multi-targeted tyrosine kinase inhibitor, crizotinib, in human plasma and bulk 
powder by highly sensitive micellar enhanced spectrofluorimetric procedure.  
Method: The developed procedure was based on measuring the fluorescence intensity of crizotinib 
(CRZ) in sodium dodecyl sulphate (SDS) micellar system at 404 nm after excitation at 271 nm. 
Validation of the developed procedure was carried out following ICH (International Council for 
Harmonization) guidelines. 
Results: Maximum fluorescence intensity (FI) was attained by addition of 0.2 mL SDS and 0.2 mL HCl 
(1N) to CRZ aliquots and then dilution with distilled water. There was a linear relationship between the 
FI of CRZ and its concentration over the range, 5 – 400 ng/mL, with limit of detection and of 
quantification of 1.857 and 5.628 ng/mL respectively. The developed procedure was successfully 
applied to assay CRZ in pure powder form and spiked human plasma with mean recovery of 100.68 ± 
0.37 and 99.98 ± 0.20 %, respectively. 
Conclusion: The developed procedure is simple and sensitive, and can be applied to routine analysis 
of CRZ in pure powder form as well as in clinical laboratories for the determination of CRZ in plasma.   
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Crizotinib (CRZ, Figure 1) is one of the new 
tyrosine kinase inhibitors (TKIs) which is 
chemically known as 3-[(1R)-1-(2, 6-dichloro-3-
fluorophenyl) ethoxy]-5-(1-piperidin-4-ylpyrazol-
4-yl) pyridine-2-amine. CRZ binds to the ATP-
binding pocket of the correspondent kinase in a 
competitive manner [1-4]. Its targeting kinases 
include anaplastic lymphoma kinase (ALK), 
mesenchymal-epithelial transition factor (MET), 
and other tyrosine kinases. 
 
It is used effectively in patients suffering from 
non-small cell lung cancer (NSCLC). Food and 
Drug Administration (FDA) has approved CRZ in 
2011 for the management of NSCLC due to its 
success in two clinical trials [5]. CRZ is available 
in the market under the name of Xalkori® 
capsule and is manufactured by Pfizer, Inc. The 
absorption of CRZ is not influenced by foodstuff 
and its maximum plasma concentration attained 
after 4 h following administration of one dose. 
Currently, a binary combination of CRZ and 
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dasatinib is under evaluation for treating high-
grade glioma (HGG) or diffuse intrinsic pontine 
glioma (DIPG). The positive results of using this 
binary combination may involve pharmacokinetic 
interaction between the two drugs as CRZ is 
considered an inhibitor of CYP3A. Unfortunately, 
CRZ pharmacokinetic disposition, in infants 
suffering from malignant brain tumors, is not 
known till now. Accordingly, reliable and accurate 
analytical methodology for CRZ determination is 
crucial for further pharmacokinetic studies. 
Literature review revealed that CRZ was assayed 
in plasma by liquid chromatography coupled with 
either tandem mass spectrometry [6-9] or 
fluorescence detection [10]. However, these 
chromatographic methods suffered from 
complexity and being expensive. Few 
spectrophotometric methods have been reported 
for determination of CRZ in dosage form [11-13]. 
Thus development of simple and sensitive 
analytical methodology for CRZ determination in 
plasma is demanded. Accordingly, in the current 
study a rapid, sensitive and reliable 
spectrofluorimetric method was conducted for the 
assay of CRZ in plasma. The present method 
involved micellar enhancement of FI of CRZ 
utilizing SDS as a sensing agent. Application of 
micellar enhancement approach in 
spectrofluorimetry was applied to assay small 
molecules by virtue of its high sensitivity [14-16] 
due to the ability of the formed micelle to 
decrease the free rotational motions and thus 
protect the analyte molecules from the 
radiationless deactivation process [16]. 
Additionally, this approach represents effective 
and echo-friendly methodology because there is 
no application of organic solvents throughout the 




Reagents and materials 
 
Solvents utilized in this study were of HPLC 
grade (Merck, Darmstadt, Germany) while 
chemicals were of analytical grade. Reference 
powder of CRZ (purity ~ 99.6 %) was procured 
from Weihua Pharma Co. Ltd (Zhejiang, China). 
SDS (Sodium dodecyl sulphate; 95 %) was 
purchased from Winlab (Pontefract, London, UK) 
and prepared as 1 % aqueous w/v. Cremophor 
RH 40 and Cremophor EL were procured from 
BASF (Ludwigshafen, Germany) and prepared 
as 1 % v/v aqueous solutions. Both β–CD (β–
cyclodextrin) and CMC (carboxymethylcellulose) 
were procured from Merck (Darmstadt, 
Germany) and prepared as 1 % w/v aqueous 
solutions. Tween 20, tween 80 and tween 85 
were procured from Techno Pharmchem 
Haryana Company (New Delhi, India) and 
prepared as 1 % v/v aqueous solution. Ethanol 
and methanol were purchased from VWR 
Prolabo (Fontenay Sous Bois, France) and 
acetonitrile was purchased from Sigma-Aldrich 
Chemie GmbH (Schnelldorf, Germany). 0.1 M 
Phosphate buffer and 0.1 M borate buffer, 
covering the pH ranges 2–12 were freshly 
prepared and ultrapure water was acquired 
through a Millipore Milli-Q® UF Plus water 
purifier (MA, USA). Plasma samples were 
obtained from King Khaled University Hospital 
(KSU, Riyadh, Saudi Arabia). All patients 
provided written informed consent, then fasting 
blood specimens were collected followed by 




Normal fluorescence measurements were 
recorded utilizing Jasco FP-8200 Fluorescence 
Spectrometer (Jasco Corporation, Japan) fitted 
with a xenon lamp (150 W) and standard 10 mm 
pathlength quartz cell with bandwidth of 5 nm for 
both excitation and emission monochromators. 
Quinine sulphate solution (0.01 µgmL-1) was 
frequently utilized for calibration of Fluorescence 
Spectrometer. Data acquisition was executed by 
SpectraManager® software. pH measurements 
were done utilizing Hanna pH-Meter (Romania). 
 
Preparation of standard stock and working 
solutions 
 
Accurately quantity of CRZ (25 mg) was weighed 
and transferred into a 25 mL measuring flask, 
dissolved in methanol and made up t to mark 
with same solvent to prepare a stock solution of 
CRZ (1 mg/mL). CRZ stock solution was diluted 
afterwards with methanol to prepare working 
standard solution of 1 μg/mL. For fourteen days, 
these standard solutions were stable when 
stored in the refrigerator. 
 
Sample preparation and generation of 
calibration curve  
 
Calibration samples were prepared by accurately 
transferring aliquots of CRZ standard solutions to 
five mL calibrated flasks followed by addition of 
0.2 mL of SDS and 0.2 mL of HCl (1 N) and 
completing volume by ultrapure distilled water to 
yield final concentrations of 5 - 400 ng/mL. 
Mixing of the flasks’ contents took place followed 
by recording FI at 404 nm after excitation at 271 
nm. Calibration curve was generated by plotting 
FI of calibration samples versus CRZ 
concentrations in ng/mL. Finally, the regression 
equation was computed and utilized to calculate 
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CRZ concentrations in different samples 
depending on their FI. 
 
Analysis of human plasma samples 
 
Accurate volume (20 µL) of standard solutions of 
CRZ (correspond to different concentrations of 
CRZ)) were spiked individually to a one mL 
portion of free drug human plasma and mixed 
well for 1 min to yield CRZ final concentrations of 
150, 200 and 250 ng/mL. Thereafter, addition of 
1 mL of NaOH (100 mM) /glycine buffer pH 12 
and the Eppendorf tube was vortexed for 10 s. 
Afterwards, 5 mL of diethyl ether was added 
Tube was then vortexed once again for 30 s and 
then centrifuged at 10,000 rpm for 15 min for 
complete phase separation. Accurate volume of 
the upper organic layer was transferred to glass 
vials and dried using gentle stream of nitrogen. 
Ultimately, reconstitution of the residue took 
place in methanol and general steps of 
calibration curve generation were followed. Blank 
plasma samples were treated and prepared in a 
similar way. FI of CRZ was measured at the 
emission wavelength (404 nm) after excitation at 
271 nm, then concentrations of CRZ were 
calculated from calibration graph of the drug 




In the current study, micellar enhanced 
spectrofluorimetric method was developed for 
assaying CRZ (Figure 1) in plasma. This 
approach is characterized by the simplicity and 
sensitivity of spectroscopic technique that 
enables one to quantify CRZ in plasma. Hence, 
this approach is considered a typical alternative 
to the reported chromatographic methods for 
quantitation of CRZ in plasma. Different 
parameters affecting FI of CRZ were studied and 
optimized using one factor at a time in the 
optimization studies. Fluorescence spectra of 
CRZ in water and SDS micellar medium are 




Figure 1: Chemical structure of Crizotinib (CRZ) 
 
Experimental conditions optimization  
 
Several experiments were performed to optimize 
the different parameters that affect the FI of CRZ. 
First of all, different types of organized media 
were added to aliquots of CRZ solution to inspect 
their effect on CRZ response. These organized 
media included SDS as an example for anionic 
surface active agent, 
 
Figure 2: Excitation (1) and emission (2) spectra of CRZ (100 ng/mL) in SDS (1 %, w/v); (A) excitation (3) and 
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tween 20, 80 and 85, Cremophor El, Cremophor 
RH 40 as examples for nonionic surface active 
agents in addition to carboxymethyl cellulose 
(CMC), and macromolecules such as β-
cyclodextrin. Accordingly, 0.5 mL of various 
organized media was added to CRZ standard 
solution. The best result was acquired by 
addition of SDS as seen in Figure 3. 
 
Different volumes of 1 % w/v aqueous solution of 
SDS were added to CRZ standard solution. 
Figure. 4 anticipated that maximum FI of CRZ 
was attained by addition of 0.2 mL SDS. Any 
further increase in volume of SDS did not affect 
the FI of the cited drug and as a result, 0.2 mL 1 
% w/v SDS solution was chosen throughout the 
study.  
 
The effect of pH was also studied by adding 
different buffers to CRZ solution. The whole pH 
range was covered utilizing HCl, 0.1 M borate 
buffer and 0.1 M borate buffer individually. The 
data showed that maximum FI was recorded 
utilizing 1 N HCl (pH < 1) and on increasing pH, 
the FI decreased markedly as anticipated in 
Figure 5. 
 
From these data, it was believed that at low pH, 
CRZ is in the cationic form and thus interact 
favorably with the SDS negative sulphonyl 
(OSO3−) group. Calculations carried out by 
Chemicalize [17] supported this thought which 
pointed out that the CRZ acquired maximum 
positive charge at low pH which in turn reflects 
that the cationic form of CRZ is the dominant 
form. The suggested interaction between CRZ 
and SDS is displayed in Scheme 1. 
 
Figure 3: Effect of the type of organized media (0.2 mL, 1 % w/v solution of each) on fluorescence intensity of 




Figure 4: Effect of Sodium dodecyl sulfate  (SDS) volume (1 % w/v) on fluorescence intensity of CRZB (100 
ngmL-1) 
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Figure 5: Effect of pH on the FI of 100 ng/mL CRZ in 0.2 mL 1 %, w/v  Sodium dodecyl sulfate (SDS) solution in 
water (black column CRZ with surfactant, white column CRZ without surfactant and gray column surfactant only) 
 
 
Scheme 1: Suggested mechanism for CRZ-SDS micelle formation 
 
Ultimately, the factor of dilution was taken into 
account by adding various solvents such as; 
water, methanol, ethanol and acetonitrile. The 
response was almost equal utilizing different 
solvents as displayed in Figure 6. Accordingly, 
water was used for dilution to increase the 
greenness of the proposed method. The stability 
of FI of CRZ was also studied versus time and it 
was revealed that the fluorescence property of 
CRZ in SDS micellar medium was developed 




Linearity and sensitivity 
 
Method linearity was confirmed by generation of 
the calibration curve through plotting the FI of 
CRZ, as y-axis, against the corresponding 
amounts of CRZ in ng/mL, as x-axis. Linearity of 
CRZ in organized medium (SDS) ranged 
between 5 and 400 ng/mL as depicted in Table 
1. Statistical results [18] were also displayed in 
Table 1 showing minimal values of; standard 
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deviation of slope, standard deviation of intercept 
and standard deviation of residuals in addition to 
low values of % RSD and % error for triplicate 
samples. Additionally, determination coefficient 
value was almost equal unity. These above-
mentioned values confirmed the linearity of the 
adopted method. Additionally, method linearity 
was checked by plotting ratio of fluorescence 
intensity- CRZ concentration (as y-axis) against 
log CRZ concentration (as x-axis) as shown in 
Figure 7 [19]. 
 
For assessment of method sensitivity, limits of 
quantification (LOQ) and detection (LOD) were 
found to be 5.628 and 1.857 respectively. LOQ 
and LOD were calculated utilizing the following 
equations: 
LOQ = 10(ρ/n)…………….…………. (1) 
 
LOD = 3.3(ρ/n)………………………. (2) 
 
where, ρ and n are the standard deviation of 
intercept and slope of regression line slope, 
respectively. The results are displayed in Table 
1.  
 
Literature [20] revealed that peak plasma 
concentration of CRZ is 274 ng/mL, which is 
quite higher than the LOQ of our adopted 
method, and therefore, determination of CRZ in 






Figure 6: Effect of the diluting solvent on fluorescence intensity of CRZ (100 ng/mL); white column without 
surfactant and black column with surfactant 
 
 
Figure 7: Validation of linearity of the analytical method of CRZ 
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Table 1: Analytical performance data for the 
spectrofluorimetric determination of CRZ 
 
Parameter CZB 
Wavelength [λex/ λem] (nm) 271/404 
Linearity range (ng/mL) 5-400 
Intercept (a) - 5.810 
Slope (b) 16.24 
Correlation coefficient (r) 0.9999 
S.D. of residuals (Sy/x) 36.90 
S.D. of intercept (Sa) 9.140 
S.D. of slope (Sb) 0.0502 
% RSDa 0.355 
% Errorb -0.699 
LOD (ng/mL) c 1.857 
LOQ (ng/mL) d 5.628 
a % Relative standard deviation (n = 3); b % relative 
error for three replicate samples; c limit of detection; d 
limit of quantitation 
 
Accuracy and precision 
 
Accuracy, intra- and inter-day precisions were 
computed following the guidelines stated by 
International Conference on Harmonization (ICH) 
for validation of analytical procedures [21]. 
Results of accuracy and precisions were 
displayed in Tables 2 and 3. For calculation of 
intra- and inter-day precisions, triplicate samples 
corresponding to four different concentrations of 
CRZ were assayed in one day and in three 
different successive days respectively. 
Precisions were labelled in terms of percentages 
recovery. Average percentage recovery was 
around 100 % and RSD values were low (Table 
3). Accuracy was described in terms of % RSD 
and standard error of mean (SEM). The small 
values of both % RSD and SEM were indicative 





Table 4 summarized the results of the method 
robustness by evaluating the liability of 
determinations to deliberate changes of the 
experimental conditions. It was found that small 
changes that possibly occur during the 
experimental runs will have no significant effect 
on the fluorescence intensity of the cited drug. 
The temperature values were kept constant by 




Method selectivity was evaluated by assaying 
CRZ in plasma (as an example for biological 
matrix). Table 5 displayed the results for analysis 
of plasma samples, indicating the selectivity of 
the suggested procedure as there was no 

















1 10 10.07 0.316 100.72 3.136 0.182 
2 10 10.12 0.154 101.24 1.523 0.089 
3 10 10.07 0.275 100.66 2.735 0.159 
1 100 99.24 1.475 99.24 1.487 0.852 
2 100 100.86 1.326 100.86 1.315 0.766 
3 100 99.52 0.869 99.52 0.873 0.501 
1 200 200.7 0.945 100.35 0.471 0.545 
2 200 200.71 0.741 100.36 0.369 0.428 
3 200 203.27 0.71 101.64 0.349 0.41 
1 300 301.06 1.071 100.35 0.356 0.618 
2 300 307.48 3.16 102.49 1.028 1.824 
3 300 304.11 2.103 101.37 0.692 1.214 
SEM = standard error of the mean; 1, 2 and 3 represents measurements obtained on day 1, day 2 and day 3, 
respectively ( n = 3 for each day) 
 












Recovery (%, ± 
RSD) a 
10 10.07 100.87±0.316 10.07 99.50±1.475 
100 99.24 99.87±0.869 99.52 99.03±1.326 
200 200.7 100.78±0.741 203.27 100.67±0.819 
300 301.06 100.41±1.071 304.11 100.36±1.68 
a Mean of three determinations 
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Table 4: Robustness of the proposed 
spectrofluorimetric method 
 
Parameter variation Recovery (%, ± SD a 
No variation b 99.68 ± 0.88 
SDS volume (µL)  
180 100.02±2.223 
220 102.79±0.545 
Acid concentration (N)  
0.8 101.31±1.306 
1.2 104.25 ±0.631 
Acid volume (µL)  
0.95 100.07± 0.545 
1.05 104.25± 0.452 
Temperature (C °)  
20 103.33 ± 0.770 
30 098.25± 0.981 
a Mean of three determinations; b following the general 
calibration procedures 
 
Table 5: Assay results for CZB in pure form and 
human plasma samples 
 









40 100.83 150 99.9 
100 100.26 200 99.98 
300 100.95 250 0.2 
Mean 100.68  99.98 
± S.D. 0.367  0.199 
 
Application to CRZ in human plasma 
 
The suggested spectrofluorimetric procedure 
was applied for assaying CRZ in plasma 
samples. The maximum plasma concentration of 
CRZ is reached after oral administration of a 
single CRZ dose of 250 mg by 4 h [22]. The Cmax 
of CRZ is reported to be 274 ng/mL [20]. 
Accordingly, CRZ could be assayed efficiently by 
the adopted method as the Cmax lied in our 
dynamic range (Table 1). Mean of the relative 
recoveries and % RSD of CRZ in plasma 
samples are presented in Table 5 (99.98 and 




Fluorescence spectrum of any molecule depends 
on absorbing of electromagnetic radiation by the 
molecule. On examining the fluorescence 
behavior of CRZ, it was found that CRZ exhibited 
two peaks. The first one represented the 
excitation band with maximum intensity at 271 
nm while the other one represented the emission 
band with maximum intensity at 404 nm.  
 
This indicated the intrinsic fluorescence property 
of CRZ. As a trial to increase the FI of CRZ and 
hence the sensitivity of the proposed method, 
different surfactants were added to CRZ solution.  
It was found that addition of SDS, an anionic 
surfactant, led to increment of CRZ fluorescence 
intensity by enhancement of its absorption at 271 
nm (excitation wavelength). This was confirmed 
by calculation of the molar absorptivity of CRZ in 
SDS (εmicellar) and that of CRZ in HCl solution 
(εHCl) at 271 nm. The value of εmicellar was 
5.085x10 5 while that of εHCl was 3.3 × 105. Upon 
calculation of quantum yield of CRZ in SDS and 
HCl respectively, it was noticed that there is no 
difference between the two values at 271 nm 
indicating that the enhanced effect of SDS was 
due to increasing CRZ molar absorptivity only.  
 
The quantum yield of CRZ in SDS medium was 
calculated Eq 3 [15]:  
 
∅c = ∅q(Fc/Fq × Aq/Ac) ………………….. (3) 
 
where ∅c and ∅q are the quantum yields of CRZ 
in SDS medium and quinine, respectively. Fc and 
Fq are the integral fluorescence intensities of the 
CRZ and quinine, respectively; Ad and Aq are 
the absorbance values of CRZ and quinine at 
excitation wavelength, respectively. In order to 
reduce the error of the inner effect, we selected 





The current work is the first spectrofluorimetric 
approach, to the best of our knowledge, for the 
assay of CRZ in spiked human plasma samples 
as well as bulk powder form. The adopted 
method, based on measuring native fluorescence 
of the cited drug, is sensitive and simple and 
gave reproducible results for CRZ determination 
in very low concentration levels.  
 
Another advantage is the green nature of the 
method because no organic solvent was used 
except during extraction of CRZ from plasma 
matrix. Thus, the developed procedure can be 
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